Inside Diagnostics BRCA tumour testing: from sample processing to result interpretation

An important percentage of ovarian cancers is associated with mutations in breast cancer 1 or 2 (BRCA1 or BRCA2) genes. Because ovarian cancer tumours that contain BRCA mutations can be treated with poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors, BRCA tumour testing has become a standard for diagnostics-based therapy choice in ovarian cancer patients. In this regard, it is crucial for institutions to conduct high-quality, validated BRCA tumour testing to ensure that the patients receive the correct results in a timely manner.

In a webinar available now on the IDBRCA platform, Dr. Carina Heydt (Institute of Pathology, University Hospital Cologne, Germany) covers in detail the technical and practical aspects of performing BRCA tumour testing. Those willing to implement BRCA testing in their laboratory and those new to the procedure will benefit from this “in lab” end-to-end tutorial, which spans from sample processing to data analysis and interpretation. Current options for each step and practical tips are included in the presentation, as well as a dedicated section on how to validate the BRCA testing process before it can be applied to the clinical use.

NS ID XL-0192-RD11/2017-LB


Rudy Hovelinck
Diagnostics Manager at AstraZeneca


NS ID BE-1389-RD11/2017-LB

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

M. +32 (0) 476 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.